Lung Cancer | Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Immunotherapy and Other Nontargeted Approaches for Lung Cancer

Featuring perspectives from Dr Matthew Gubens, including the following topics: Introduction: Risk of Autoimmune Toxicity with Checkpoint Inhibitors (0:00) Immunotherapy in the Neoadjuvant/Adjuvant Setting (7:33) Immunotherapy for Locally Advanced Non-Small Cell Lung Cancer (NSCLC) (15:45) First-Line Immunotherapy for Metastatic NSCLC (24:04) Novel Agents and Strategies (30:39) Immunotherapy for NSCLC with a Targetable Mutation (41:34) Small Cell Lung Cancer (47:06) CME information and select publications